Iasella CJ, Winters SA, Kois A, et al. - In view of the observation that in lung transplant recipients (LTRs), Epstein-Barr virus (EBV)–associated posttransplant lymphoproliferative disorder (EBV-PTLD) is a serious complication that is associated with significant mortality, researchers evaluated the risks for PTLD in LTRs over a 7-year period in this single-center retrospective study. Six hundred eleven evaluable LTRs were identified; of these, 28 cases had PTLD, with an incidence of 4.6%. A decreased freedom from PTLD in idiopathic pulmonary fibrosis (IPF)-LTRs was observed in Kaplan-Meier analysis. A multivariable Cox proportional hazards model revealed IPF and alemtuzumab induction therapy as risk factors for PTLD, vs EBV mismatch. Early PTLD (first year) was linked with alemtuzumab use, while for late PTLD (after first year), IPF was a predictor, after controlling for age and gender. As per Kaplan-Meier analysis, IPF LTRs report a shorter time to death from PTLD vs other patients.